CytRx has reported positive results of the study evaluating arimoclomol. The data demonstrated that arimoclomol exhibited both significant neuroprotective and neuroregenerative effects in brain cells of animals induced
Myoderm, a pharmaceutical supplier of comparator drugs for clinical research and clinical trials, has expanded its portfolio to include Distribution Management Services. Reportedly, this new capability provides their
Bavarian Nordic has announced that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE smallpox vaccine. The company said
ARIAD Pharmaceuticals and its co-plaintiffs have announced that the US Court of Appeals for the Federal Circuit has granted their petition for rehearing en banc, and has vacated
GxP Consulting has announced expansion plans in the US and UK markets. Led by Mark Stevens, managing director at GxP Consulting, the company has launched a strategy to
Celentyx has entered into a drug reprofiling agreement with Meiji Seika Kaisha to seek alternative development paths for Meiji drug candidates, using an application of the Immuno-Profiling platform
National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has awarded a $30.9m, five-year contract to Nanotherapeutics. The deal is intended
Ranbaxy Laboratories has received approval from the US Food and Drug Administration (FDA) to manufacture and market Glycopyrrolate Tablets USP, 1mg and 2mg. The Ranbaxy formulations is bioequivalent
Novartis has reported that the European Commission (EC) has approved Xolair (omalizumab) as add-on therapy for severe persistent allergic asthma in children aged 6 to 11 years. Reportedly,
Santhera and Biovail have signed a license agreement for Santhera’s JP-1730/fipamezole. Biovail has acquired the US and Canadian rights to develop and commercialise the drug for the treatment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.